High-resolution oligonucleotide analysis with capillary gel electrophoresis

As oligonucleotide therapeutics continue to grow in importance across cell and gene therapy, CRISPR-based medicines, and biopharmaceutical development, robust analytical methods for sizing, purity, and integrity assessment are becoming essential for development and quality control.

In this 20-minute TechTalk, Aaron Stella, Senior Scientist at SCIEX, will explore how high-resolution capillary gel electrophoresis (CGE) can deliver single-nucleotide resolution across an expanded oligonucleotide size range, supporting confident characterization of oligonucleotides up to 200 nucleotides.

Drawing on his experience in analytical technology development and clinical laboratory workflows, he will also share real-world application examples, including poly(A) tail analysis, and explain how the new Oligo 200 nt Purity and Integrity kit can help simplify workflows while enabling robust, reproducible oligonucleotide analysis on the BioPhase 8800 system.

Certificate of attendance

• If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. 
• If you view the on-demand TechTalk, you can request a certificate of attendance by emailing [email protected].

TechTalk details

• Cost: Free to attend
• Location: Online
• Duration: 20 minutes

What will this webinar cover?

• Why single-nucleotide resolution is critical for modern oligonucleotide therapeutic development and quality control
• How high-resolution CGE overcomes challenges associated with analyzing larger oligonucleotides
• How the new Oligo 200 nt Purity and Integrity kit enables robust sizing, purity assessment, and streamlined analytical workflows for oligonucleotides up to 200 nt

Speaker: Aaron Stella (Senior Scientist, SCIEX)

Aaron Stella is a Senior Scientist in SCIEX Chemistry R&D with expertise in clinical diagnostics and analytical laboratory workflows. Drawing on experience at both SCIEX and Mayo Clinic Laboratories New England, he collaborates with scientists, product teams, and R&D leaders to advance the next generation of analytical technologies. By connecting emerging scientific challenges with innovative solutions, he helps drive the development of tools that enable more informed decision-making and accelerate progress across the biopharmaceutical industry.